Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-Arginine for anti-VEGF induced kidney injury
NCT02882373Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2018
- Primary completion
- May 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arginine in nephropathy, hypertension (HTN), proteinuria, sponsored by University of Texas MD Anderson Cancer Center. Planned start Oct 2018; status: withdrawn.
02
Drugs
arginine
03
Conditions
nephropathyhypertension (HTN)proteinuria
Beyond the preview
Go deeper on NCT02882373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02882373.